CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 23, 2018
Result type: Reports
Project Number: SR0438-000
Product Line: Reimbursement Review

Generic Name: Riociguat

Brand Name: Adempas

Manufacturer: Bayer Inc.

Therapeutic Area: Pulmonary arterial hypertension (WHO group 1)

Indications: Pulmonary arterial hypertension (WHO group 1)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: December 17, 2015

Recommendation Type: List with clinical criteria and/or conditions